Repatha (evolocumab) is an injectable medicine that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol. Approved in 2015, Repatha can now be used in adults ...

The US Food and Drug Administration has expanded the indication for evolocumab (Repatha) to include a wider swath of patients at high risk for cardiovascular disease due to elevated LDL cholesterol ...

PARIS — Adding the PCSK9 inhibitor evolocumab (Repatha, Amgen) to high-intensity statin therapy in the very high-risk setting of acute coronary syndrome (ACS) safely lowers low-density lipoprotein ...

IOWA CITY, IA — The LAPLACE-2 study, a 12-week randomized, clinical trial that demonstrated the clinical effectiveness of adding the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor ...

Elderly patients with atherosclerotic cardiovascular disease (ASCVD) treated long-term with the PCSK9 inhibitor evolocumab (Repatha; Amgen) derive as much clinical benefit as younger people, according ...

After coronary artery bypass grafting (CABG), evolocumab did not reduce saphenous vein graft disease rates at 2 years compared with placebo, according to late-breaking research presented in a Hot Line ...